Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• BCR/ABL tyrosine kinase is crucial for activating phosphatidylinositol-3 kinase (PI-3k)/Akt and signal transducer and activator of transcription 5 (STAT5) pathways in hematopoietic cells.
• Previous studies highlighted the requirement of BCR/ABL SH2 and SH3+SH2 domains for immediate activation of these pathways.

Purpose of the Study:

• To investigate the reversibility of activation defects in PI-3k/Akt and STAT5 pathways caused by BCR/ABL mutants lacking SH2 or SH3+SH2 domains.
• To elucidate the mechanisms and consequences of Akt and STAT5 're-activation' in the absence of functional BCR/ABL domains.

Main Methods:

• Utilized BCR/ABL DeltaSH2 and DeltaSH3+DeltaSH2 mutants in hematopoietic cells.
• Employed in vitro culture to assess 're-activation' of Akt and STAT5.
• Administered BCR/ABL tyrosine kinase inhibitor STI571 to evaluate kinase dependency.
• Analyzed activation of PI-3k, Jak-2, and IL-3/IL-5/GM-CSF receptor common beta subunit phosphorylation.

Main Results:

• Defects in Akt and STAT5 activation by BCR/ABL mutants were reversible upon in vitro culture.
• 'Re-activated' Akt and STAT5 conferred increased apoptosis resistance, growth factor-independent proliferation, and leukemogenesis in SCID mice.
• STI571 treatment abrogated 're-activation' in some clones, while others showed BCR/ABL-independent activation.
• Alternative pathway activation (PI-3k, Jak-2) and common beta subunit phosphorylation were observed.

Conclusions:

• Re-activation of Akt and STAT5 in BCR/ABL mutants can occur through BCR/ABL kinase-dependent alternative pathways or BCR/ABL-independent genetic alterations.
• These findings reveal distinct mechanisms driving leukemogenesis beyond direct BCR/ABL kinase activity.